ArticleThe American journal of clinical nutrition2025
Lignan Intake and Mortality Among Adults with Incident Type 2 Diabetes-Prospective Cohort Studies.
Article in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diet-Microbiome Analysis in a Healthy Cohort Reveals Potential Role of Intestinal Microbiota in Metabolism.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLignans are polyphenolic compounds abundant in plant-based foods such as seeds, whole grains, and certain fruits and vegetables and may lead to favorable metabolic health. It remains to be elucidated regarding the role of lignan consumption in the etiology of premature deaths among individuals with diabetes.
objectivesTo prospectively examine the association between postdiagnosis lignan intake and mortality among individuals with type 2 diabetes (T2D).
methodsWe analyzed data from 2 prospective United States cohorts, the Nurses' Health Study (1984-2020) and Health Professionals Follow-up Study (1986-2022). Mean daily consumption of total and individual lignans was calculated, and postdiagnosis lignan intakes were cumulatively averaged. Multivariable-adjusted Cox models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between lignan intake and mortality.
resultsAmong 8465 incident T2D cases contributing 116,026 person-years of follow-up, 4372 deaths were documented, including 1318 from cardiovascular disease (CVD) and 752 from cancer. The pooled multivariable-adjusted HRs (95% CIs) of all-cause mortality comparing the highest compared with the lowest quintiles of postdiagnosis lignan intake were 0.83 (0.74, 0.94) for total lignans, 0.89 (0.80, 0.99) for matairesinol (MAT), 0.78 (0.69, 0.87) for secoisolariciresinol (SECO), 0.91 (0.81, 1.01) for pinoresinol (PINO), and 0.92 (0.82, 1.03) for lariciresinol (LARIC). Higher postdiagnosis SECO intake was also significantly associated with lower CVD and cancer mortality. Changes in lignan intake from pre- to postdiagnosis showed similar favorable associations: 0.83 (0.75, 0.93) for total lignans, 0.86 (0.77, 0.96) for MAT, and 0.81 (0.72, 0.90) for SECO. The associations of lignan intake were significantly stronger among nonwhite individuals.
conclusionsAmong individuals with T2D, a higher intake of lignans, particularly SECO, was significantly associated with reduced overall CVD and cancer mortality. Minority groups may particularly benefit from lignan intake, although further studies are warranted to substantiate this observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.